Iterum Therapeutics plc (ITRM)
After hours:
| Previous close | 1.5000 |
| Open | 1.5200 |
| Bid | 1.4700 x 100 |
| Ask | 1.5300 x 100 |
| Day's range | 1.4700 - 1.5499 |
| 52-week range | 0.6220 - 2.5000 |
| Volume | |
| Avg. volume | 172,368 |
| Market cap | 24.996M |
| Beta (5Y monthly) | 2.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.50 |
- Thomson Reuters StreetEvents
Q1 2024 Iterum Therapeutics PLC Earnings Call
Q1 2024 Iterum Therapeutics PLC Earnings Call
GlobeNewswireIterum Therapeutics Reports First Quarter 2024 Financial Results
--NDA Resubmitted; FDA Action Expected in Early Q4 24-- --Cash Runway into 2025, including through Potential FDA Approval-- --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN, Ireland and CHICAGO, May 13, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum) a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, to
- GlobeNewswire
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Monday, May 13, 2024. Management will host a
